One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study
Transplant International · 2025
DOI: 10.3389/ti.2025.14940 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Transplant International, 2025. Verfasst von Georgios Kourounis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Hauptthemen laut MEDLINE: Graft Survival, Glycated Hemoglobin, Pancreas Transplantation, Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Institute for Health and Care Research.
Abstract (Originalsprache)
Understanding which factors shape long-term pancreas graft outcomes after the critical first year post-transplantation is an ongoing challenge. This study assesses one-year HbA1c as a predictor of subsequent pancreas graft survival. A retrospective cohort study was conducted using the UNOS registry on all simultaneous pancreas-kidney (SPK) transplants between 2017 and 2023. Regression models with multiple imputations for missing data were used to evaluate predictors of long-term function. Non-linear relationships were modelled with restricted cubic splines (RCS). Among 2,917 SPK recipients (median follow-up 44 months, IQR: 25–60), one-year HbA1c was the strongest independent predictor of long-term graft survival. An HbA1c of 6.8% versus 4.4% (95th vs. 5th percentile) was associated with significantly worse graft survival (aHR = 2.48, 95% CI: 1.72–3.58). Simulated trial sample size calculations found that detecting a statistically and clinically significant reduction in one-year HbA1c from 7% to 6.5% would require 65 patients per group, whereas detecting a reduction in one-year graft loss from 12% to 9% would require 1,631 patients per group. HbA1c at 1 year is a robust, continuous marker of long-term graft function and may serve as a feasible, objective surrogate endpoint in future clinical trials, enabling smaller, more efficient study designs to evaluate interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
- NIHR Blood and Transplant Research Unit, Newcastle University and Cambridge University, Newcastle upon Tyne, United Kingdom.
- Institute of Transplantation, The Freeman Hospital, Newcastle upon Tyne, United Kingdom.
- Recanati/Miller Transplantation Institute, Mount Sinai Hospital, New York, NY, United States.
Förderung
- Medical Research Council
- National Institute for Health and Care Research
Zitieren
APA
Kourounis, G., Tingle, S. J., Maillo-Nieto, A., Wroe, C., Thompson, E. R., Owen, R., van Leeuwen, L., Holzner, M., Wadhera, V., Zeeshan Akhtar, M., Florman, S., Shaw, J., White, S., & Wilson, C. (2025). One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study. Transplant International. https://doi.org/10.3389/ti.2025.14940
Vancouver
Kourounis G, Tingle SJ, Maillo-Nieto A, Wroe C, Thompson ER, Owen R, et al. One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study. Transplant International. 2025. doi:10.3389/ti.2025.14940
BibTeX
@article{Kourounis2025,
author = {Kourounis, Georgios and Tingle, Samuel J and Maillo-Nieto, Angeles and Wroe, Caroline and Thompson, Emily R and Owen, Ruth and van Leeuwen, Leonie and Holzner, Matthew and Wadhera, Vikram and Zeeshan Akhtar, Mohammed and Florman, Sander and Shaw, James and White, Steve and Wilson, Colin},
title = {One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.14940}
}
EUVIMED